東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Hereditary tyrosinemia = pathogenesi...

Tanguay, Robert M.

Linked to FindBook

Google Book

Amazon

博客來

Hereditary tyrosinemia = pathogenesis, screening and management /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Hereditary tyrosinemia/ edited by Robert M. Tanguay.
Reminder of title:	pathogenesis, screening and management /
other author:	Tanguay, Robert M.
Published:	Cham :Springer International Publishing : : 2017.,
Description:	xv, 247 p. :ill. (some col.), digital ;24 cm.
[NT 15003449]:	Section I: Tyrosinemia Type 1: Heredity -- Section II:The Molecular Basis of HTI -- Section III: Pathology -- Section IV: Screening, Management and The Future.
Contained By:	Springer eBooks
Subject:	Tyrosinosis - Diagnosis. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-55780-9
ISBN:	9783319557809

Hereditary tyrosinemia = pathogenesis, screening and management /
Hereditary tyrosinemiapathogenesis, screening and management /[electronic resource] :edited by Robert M. Tanguay. - Cham :Springer International Publishing :2017. - xv, 247 p. :ill. (some col.), digital ;24 cm. - Advances in experimental medicine and biology,v.9590065-2598 ;. - Advances in experimental medicine and biology ;v.959..

Section I: Tyrosinemia Type 1: Heredity -- Section II:The Molecular Basis of HTI -- Section III: Pathology -- Section IV: Screening, Management and The Future.

Hereditary tyrosinemia type 1 (HT1), the most severe inborn error of the tyrosine degradation pathway, is due to a deficiency in fumarylacetoacetate hydrolase (FAH) The worldwide frequency of HT1 is one per 100,000 births, but some regions have a significantly higher incidence (1:1,800) The FAH defect results in the accumulation of toxic metabolites, mainly in the liver. If left untreated, HT1 is usually fatal before the age of two. HT1 patients develop several chronic complications including cirrhosis with a high risk of hepatocellular carcinoma (HCC) and neuropsychological impairment. Treatment comprises an inhibitor of the pathway, Nitisinone, a strict dietary treatment or liver transplantation. Early treatment is important to avoid HCC. The book includes the latest developments on the molecular basis of HT1, its pathology, screening and diagnosis and management of the disease written by leading scientists, geneticists, hepatologists and clinicians in the field.

ISBN: 9783319557809

Standard No.: 10.1007/978-3-319-55780-9doiSubjects--Topical Terms:

3250215
Tyrosinosis
--Diagnosis.

LC Class. No.: RC632.T9

Dewey Class. No.: 616.399

Hereditary tyrosinemia = pathogenesis, screening and management /
LDR:02192nmm a2200325 a 4500 001 2105405
003 DE-He213
005 20170728153844.0
006 m d
007 cr nn 008maaau
008 180417s2017 gw s 0 eng d
020 $a 9783319557809 $q (electronic bk.)
020 $a 9783319557793 $q (paper)
024 7 $a 10.1007/978-3-319-55780-9 $2 doi
035 $a 978-3-319-55780-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC632.T9
072 7 $a PSBC $2 bicssc
072 7 $a SCI007000 $2 bisacsh
082 0 4 $a 616.399 $2 23
090 $a RC632.T9 $b H542 2017
245 0 0 $a Hereditary tyrosinemia $h [electronic resource] : $b pathogenesis, screening and management / $c edited by Robert M. Tanguay.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a xv, 247 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.959
505 0 $a Section I: Tyrosinemia Type 1: Heredity -- Section II:The Molecular Basis of HTI -- Section III: Pathology -- Section IV: Screening, Management and The Future.
520 $a Hereditary tyrosinemia type 1 (HT1), the most severe inborn error of the tyrosine degradation pathway, is due to a deficiency in fumarylacetoacetate hydrolase (FAH) The worldwide frequency of HT1 is one per 100,000 births, but some regions have a significantly higher incidence (1:1,800) The FAH defect results in the accumulation of toxic metabolites, mainly in the liver. If left untreated, HT1 is usually fatal before the age of two. HT1 patients develop several chronic complications including cirrhosis with a high risk of hepatocellular carcinoma (HCC) and neuropsychological impairment. Treatment comprises an inhibitor of the pathway, Nitisinone, a strict dietary treatment or liver transplantation. Early treatment is important to avoid HCC. The book includes the latest developments on the molecular basis of HT1, its pathology, screening and diagnosis and management of the disease written by leading scientists, geneticists, hepatologists and clinicians in the field.
650 0 $a Tyrosinosis $x Diagnosis. $3 3250215
650 0 $a Tyrosinosis $x Treatment. $3 3250216
650 1 4 $a Life Sciences. $3 890838
650 2 4 $a Protein Science. $3 1067276
700 1 $a Tanguay, Robert M. $3 2156178
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v v.959. $3 3250214
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-55780-9
950 $a Biomedical and Life Sciences (Springer-11642)